The Influence of Oxygen on the Survival and Death of Photoreceptors

Valter, Krisztina; Mervin, Kyle; Maslim, Juliani; Stone, Jonathan

doi:10.1007/978-1-4615-5933-7_40

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hyperbaric oxygen (HBO) therapy exposes the patient to a barometric pressure higher than the sea level ambient pressure, increasing the transfer of oxygen into tissues [40]. The retina is a highly metabolically active tissue, and photoreceptors are very sensitive to oxygen delivery, as demonstrated by Stone et al [41]. According to them, this condition of transient hyperoxia may rescue retinal photoreceptors, probably by helping them to complete their metabolic requirements [41,42].…”

Section: Hyperbaric Oxygenmentioning

confidence: 99%

“…The retina is a highly metabolically active tissue, and photoreceptors are very sensitive to oxygen delivery, as demonstrated by Stone et al [41]. According to them, this condition of transient hyperoxia may rescue retinal photoreceptors, probably by helping them to complete their metabolic requirements [41,42]. However, despite these good premises, there are only a few studies on this innovative therapy.…”

Section: Hyperbaric Oxygenmentioning

confidence: 99%

See 1 more Smart Citation

Retinitis Pigmentosa: From Pathomolecular Mechanisms to Therapeutic Strategies

Vingolo,

Mascolo,

Miccichè

et al. 2024

Medicina

View full text Add to dashboard Cite

Retinitis pigmentosa is an inherited disease, in which mutations in different types of genes lead to the death of photoreceptors and the loss of visual function. Although retinitis pigmentosa is the most common type of inherited retinal dystrophy, a clear line of therapy has not yet been defined. In this review, we will focus on the therapeutic aspect and attempt to define the advantages and disadvantages of the protocols of different therapies. The role of some therapies, such as antioxidant agents or gene therapy, has been established for years now. Many clinical trials on different genes and mutations causing RP have been conducted, and the approval of voretigene nepavorec by the FDA has been an important step forward. Nonetheless, even if gene therapy is the most promising type of treatment for these patients, other innovative strategies, such as stem cell transplantation or hyperbaric oxygen therapy, have been shown to be safe and improve visual quality during clinical trials. The treatment of this disease remains a challenge, to which we hope to find a solution as soon as possible.

show abstract